313 related articles for article (PubMed ID: 16380412)
1. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
Goldenberg DM; Sharkey RM; Paganelli G; Barbet J; Chatal JF
J Clin Oncol; 2006 Feb; 24(5):823-34. PubMed ID: 16380412
[TBL] [Abstract][Full Text] [Related]
2. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
3. Pretargeting with the affinity enhancement system for radioimmunotherapy.
Barbet J; Kraeber-Bodéré F; Vuillez JP; Gautherot E; Rouvier E; Chatal JF
Cancer Biother Radiopharm; 1999 Jun; 14(3):153-66. PubMed ID: 10850300
[TBL] [Abstract][Full Text] [Related]
4. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
7. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Faivre-Chauvet A; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1999 Jul; 40(7):1216-21. PubMed ID: 10405144
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy.
Gruaz-Guyon A; Janevik-Ivanovska E; Raguin O; De Labriolle-Vaylet C; Barbet J
Q J Nucl Med; 2001 Jun; 45(2):201-6. PubMed ID: 11476171
[TBL] [Abstract][Full Text] [Related]
10. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
11. Pretargeted radioimmunotherapy.
Meredith RF; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pretargeting approach to image and treat tumours.
Patra M; Zarschler K; Pietzsch HJ; Stephan H; Gasser G
Chem Soc Rev; 2016 Nov; 45(23):6415-6431. PubMed ID: 27722526
[TBL] [Abstract][Full Text] [Related]
13. Novel radiolabeled antibody conjugates.
Goldenberg DM; Sharkey RM
Oncogene; 2007 May; 26(25):3734-44. PubMed ID: 17530026
[TBL] [Abstract][Full Text] [Related]
14. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
Vuillez JP; Moro D; Brichon PY; Rouvier E; Brambilla E; Barbet J; Peltier P; Meyer P; Sarrazin R; Brambilla C
J Nucl Med; 1997 Apr; 38(4):507-11. PubMed ID: 9098191
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunodetection and therapy of breast cancer.
DeNardo SJ
Semin Nucl Med; 2005 Apr; 35(2):143-51. PubMed ID: 15765377
[TBL] [Abstract][Full Text] [Related]
16. Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives.
Rouvier E; Gautherot E; Meyer P; Barbet J
Horm Res; 1997; 47(4-6):163-7. PubMed ID: 9167948
[TBL] [Abstract][Full Text] [Related]
17. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
18. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody.
Zhang M; Yao Z; Saga T; Sakahara H; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1998 Jan; 39(1):30-3. PubMed ID: 9443734
[TBL] [Abstract][Full Text] [Related]
19. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in pretargeted radioimmunotherapy.
Gruaz-Guyon A; Raguin O; Barbet J
Curr Med Chem; 2005; 12(3):319-38. PubMed ID: 15723622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
